BR112017017825A2 - semaforinas 3 não naturais e seu uso médico - Google Patents
semaforinas 3 não naturais e seu uso médicoInfo
- Publication number
- BR112017017825A2 BR112017017825A2 BR112017017825-7A BR112017017825A BR112017017825A2 BR 112017017825 A2 BR112017017825 A2 BR 112017017825A2 BR 112017017825 A BR112017017825 A BR 112017017825A BR 112017017825 A2 BR112017017825 A2 BR 112017017825A2
- Authority
- BR
- Brazil
- Prior art keywords
- relates
- semaphorins
- unnatural
- polypeptides
- cancer
- Prior art date
Links
- 102000014105 Semaphorin Human genes 0.000 title abstract 3
- 108050003978 Semaphorin Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002491 angiogenic effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
Abstract
a presente invenção refere-se a moléculas de semaforina 3 de ocorrência não natural, mutadas. particularmente, a invenção refere-se a uma semaforina 3 mutada ou ao seu fragmento funcional que exibe propriedades aperfeiçoadas e efeitos farmacológicos, por exemplo, no tratamento de doença angiogênica e câncer. além disso, a presente invenção refere-se a moléculas de ácidos nucleicos que codificam tais polipeptídeos, e vetores e hospedeiros compreendendo tais ácidos nucleicos. a invenção refere-se, além disso, a métodos para a produção dos polipeptídeos da invenção, e a métodos usados no tratamento de doença, em particular, na intervenção médica de doenças angiogênicas, tumores e/ou câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15156195 | 2015-02-23 | ||
| EP15156195.8 | 2015-02-23 | ||
| PCT/EP2016/053750 WO2016135130A1 (en) | 2015-02-23 | 2016-02-23 | Non-natural semaphorins 3 and their medical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017825A2 true BR112017017825A2 (pt) | 2018-04-10 |
Family
ID=52596769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017825-7A BR112017017825A2 (pt) | 2015-02-23 | 2016-02-23 | semaforinas 3 não naturais e seu uso médico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10906948B2 (pt) |
| EP (1) | EP3262064A1 (pt) |
| JP (1) | JP6959869B2 (pt) |
| KR (1) | KR20170138410A (pt) |
| CN (1) | CN107810192A (pt) |
| AU (1) | AU2016223584B2 (pt) |
| BR (1) | BR112017017825A2 (pt) |
| CA (1) | CA2976593A1 (pt) |
| IL (1) | IL253872B (pt) |
| RU (1) | RU2722832C2 (pt) |
| SG (1) | SG11201706211PA (pt) |
| WO (1) | WO2016135130A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016287787B2 (en) | 2015-06-29 | 2021-10-28 | The University Of British Columbia | B1SP fusion protein therapeutics, methods, and uses |
| WO2017007031A1 (ja) * | 2015-07-09 | 2017-01-12 | 学校法人順天堂 | 子宮体がんのリンパ節転移能の評価方法 |
| WO2019207051A1 (en) | 2018-04-25 | 2019-10-31 | Università Degli Studi Di Torino | Medical use of combinations of non-natural semaphorins 3 and antimetabolites |
| CN109821009B (zh) * | 2019-01-22 | 2020-03-31 | 南京医科大学 | 轴突导向因子重组蛋白Semaphorin3G的医药用途 |
| CN112641928A (zh) * | 2019-10-11 | 2021-04-13 | 田中纯美 | 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途 |
| CN110684805B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用 |
| CN111009287B (zh) * | 2019-12-20 | 2023-12-15 | 东软集团股份有限公司 | SLiMs预测模型的生成方法、装置、设备和存储介质 |
| JP2023532415A (ja) * | 2020-06-04 | 2023-07-28 | メディカル リサーチ アンド ディベロップメント ファンド フォー ヘルス サービシーズ ベネイ ツィオン メディカル センター | 改変セマフォリン３ａ、それを含む組成物およびその使用 |
| CN112687338B (zh) * | 2020-12-31 | 2022-01-11 | 云舟生物科技（广州）有限公司 | 基因序列的存储和还原方法、计算机存储介质及电子设备 |
| CN114288292B (zh) * | 2021-12-10 | 2023-06-13 | 中南大学湘雅医院 | 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用 |
| EP4447958A2 (en) * | 2021-12-14 | 2024-10-23 | Radin, Daniel Pierce | Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells |
| CN115947817B (zh) * | 2023-02-22 | 2024-07-02 | 甘肃中肽生物科技有限公司 | 一种肿瘤相关多肽及其制备方法和应用 |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| EP1216258A1 (en) | 1999-09-28 | 2002-06-26 | Universität Zürich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| AU2001284703B2 (en) | 2000-08-03 | 2007-03-22 | Therapeutic Human Polyclonals Inc. | Production of humanized antibodies in transgenic animals |
| US7290975B2 (en) | 2001-03-17 | 2007-11-06 | Mechanical Tech & Engineering Co. | Two-speed passenger lift and pump assembly therefor |
| US7781413B2 (en) | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
| US7184284B2 (en) | 2004-03-30 | 2007-02-27 | Micron Technology, Inc. | Closed-loop high voltage booster |
| EP1962961B1 (en) | 2005-11-29 | 2013-01-09 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| KR20090123873A (ko) * | 2007-02-02 | 2009-12-02 | 바이오겐 아이덱 엠에이 인코포레이티드 | 수초형성 및 올리고덴드로사이트 분화 촉진을 위한 세마포린 ６ａ의 용도 |
| ES2620487T3 (es) | 2007-10-19 | 2017-06-28 | Rappaport Family Institute For Research In The Medical Sciences | Composiciones que comprenden semaforinas para uso en el tratamiento del cáncer |
| US8871205B2 (en) | 2009-11-25 | 2014-10-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
| WO2014058915A2 (en) * | 2012-10-08 | 2014-04-17 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
-
2016
- 2016-02-23 JP JP2017562129A patent/JP6959869B2/ja active Active
- 2016-02-23 CN CN201680011456.5A patent/CN107810192A/zh active Pending
- 2016-02-23 EP EP16709710.4A patent/EP3262064A1/en active Pending
- 2016-02-23 US US15/552,511 patent/US10906948B2/en active Active
- 2016-02-23 SG SG11201706211PA patent/SG11201706211PA/en unknown
- 2016-02-23 BR BR112017017825-7A patent/BR112017017825A2/pt not_active IP Right Cessation
- 2016-02-23 CA CA2976593A patent/CA2976593A1/en active Pending
- 2016-02-23 AU AU2016223584A patent/AU2016223584B2/en active Active
- 2016-02-23 RU RU2017128465A patent/RU2722832C2/ru active
- 2016-02-23 KR KR1020177026803A patent/KR20170138410A/ko not_active Application Discontinuation
- 2016-02-23 WO PCT/EP2016/053750 patent/WO2016135130A1/en active Application Filing
-
2017
- 2017-08-07 IL IL253872A patent/IL253872B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170138410A (ko) | 2017-12-15 |
| IL253872A0 (en) | 2017-10-31 |
| JP2018506994A (ja) | 2018-03-15 |
| RU2017128465A (ru) | 2019-03-25 |
| AU2016223584B2 (en) | 2020-11-19 |
| AU2016223584A1 (en) | 2017-08-17 |
| RU2017128465A3 (pt) | 2019-07-24 |
| IL253872B (en) | 2021-04-29 |
| RU2722832C2 (ru) | 2020-06-04 |
| CN107810192A (zh) | 2018-03-16 |
| JP6959869B2 (ja) | 2021-11-05 |
| EP3262064A1 (en) | 2018-01-03 |
| WO2016135130A1 (en) | 2016-09-01 |
| US20180030100A1 (en) | 2018-02-01 |
| CA2976593A1 (en) | 2016-09-01 |
| US10906948B2 (en) | 2021-02-02 |
| SG11201706211PA (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017017825A2 (pt) | semaforinas 3 não naturais e seu uso médico | |
| CL2021002094A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153) | |
| BR112018000835A2 (pt) | molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo | |
| BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
| BR112019000598A2 (pt) | rna para terapia de câncer | |
| BR112017017530A2 (pt) | proteínas específicas para pioverdina e pioquelina | |
| CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| BR112016030462A2 (pt) | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo | |
| WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| MX2020009514A (es) | Anticuerpos anti-claudina 18.2 (cldn18.2). | |
| BR112017016336A2 (pt) | proteínas de ligação icos agonistas? | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| SA517390092B1 (ar) | مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل | |
| BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
| MY196882A (en) | Recombinant binding proteins and their use | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| BR112018002130A2 (pt) | anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1) | |
| EA201792501A1 (ru) | Вакцины для лечения и профилактики рака | |
| BR112017020445A2 (pt) | polipeptídeo de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de um polipeptídeo de fusão, uso do polipeptídeo de fusão, método para ativar as vias de sinalização, método para coestimular células, método para induzir a proliferação de linfócitos e método para direcionar o agrupamento de cd137 | |
| BR112016014462A2 (pt) | moléculas de ácido nucleico artificiais | |
| BR112016028520A2 (pt) | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina | |
| MX2017000378A (es) | ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. | |
| BR112016025764A2 (pt) | vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico | |
| BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2763 DE 19/12/2023. |